Mission

The goal of the Laboratory of Hemodynamics and Cardiovascular Technology (LHTC) is to become a leading laboratory in the study of blood flow in relation to cardiovascular disease and to contribute to the advancement of medical technology through active transfer of our know-how to the clinic and to the medical technology sector.

Medical Technology and Technology Transfer

The Laboratory of Hemodynamics and Cardiovascular Technology is committed in advancing Medical Technology and Transferring the results to the private sector. Startups issued from LHTC activities are:

  1. EndoArt SA. World leader in telemetrically-controled implantable devices for the treatment of Congential Heart Disease and Morbid Obesity. Acquired by Allergan Inc. in February 2007.
  2. Antlia SA (www.ithetis.com). Developer of implantable drug delivery devices for preclinical research and vet care.
  3. Rheon Medical SA (www.rheonmedical.com). Developer of an implantable drainage device for the treatment of glaucoma
  4. Comphya Sàrl (www.comphya.com). Developer of implantable neuromodulator device for the treatment of erectile dyfunction